Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

Similar articles for PubMed (Select 11986668)

1.

Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice.

Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu DC, Gullans S, Ferrante RJ, Przedborski S, Kristal BS, Friedlander RM.

Nature. 2002 May 2;417(6884):74-8.

PMID:
11986668
2.

Nortriptyline delays disease onset in models of chronic neurodegeneration.

Wang H, Guan Y, Wang X, Smith K, Cormier K, Zhu S, Stavrovskaya IG, Huo C, Ferrante RJ, Kristal BS, Friedlander RM.

Eur J Neurosci. 2007 Aug;26(3):633-41.

PMID:
17686041
3.

Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis.

Kriz J, Nguyen MD, Julien JP.

Neurobiol Dis. 2002 Aug;10(3):268-78.

PMID:
12270689
4.

Fas small interfering RNA reduces motoneuron death in amyotrophic lateral sclerosis mice.

Locatelli F, Corti S, Papadimitriou D, Fortunato F, Del Bo R, Donadoni C, Nizzardo M, Nardini M, Salani S, Ghezzi S, Strazzer S, Bresolin N, Comi GP.

Ann Neurol. 2007 Jul;62(1):81-92.

PMID:
17503505
5.

Minocycline delays disease onset and mortality in a transgenic model of ALS.

Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W.

Neuroreport. 2002 Jun 12;13(8):1067-70.

PMID:
12060810
6.

Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO.

Scarabelli TM, Stephanou A, Pasini E, Gitti G, Townsend P, Lawrence K, Chen-Scarabelli C, Saravolatz L, Latchman D, Knight R, Gardin J.

J Am Coll Cardiol. 2004 Mar 3;43(5):865-74.

PMID:
14998631
7.

Motor neuron degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase-1 transgenic mice: mechanisms of mitochondriopathy and cell death.

Martin LJ, Liu Z, Chen K, Price AC, Pan Y, Swaby JA, Golden WC.

J Comp Neurol. 2007 Jan 1;500(1):20-46.

PMID:
17099894
8.

Involvement of mitochondrial potential and calcium buffering capacity in minocycline cytoprotective actions.

Fernandez-Gomez FJ, Galindo MF, Gomez-Lazaro M, González-García C, Ceña V, Aguirre N, Jordán J.

Neuroscience. 2005;133(4):959-67.

PMID:
15964487
9.

Re-evaluation of mitochondrial permeability transition as a primary neuroprotective target of minocycline.

Månsson R, Hansson MJ, Morota S, Uchino H, Ekdahl CT, Elmér E.

Neurobiol Dis. 2007 Jan;25(1):198-205. Epub 2006 Oct 24.

PMID:
17067803
10.

Minocycline and neurodegenerative diseases.

Kim HS, Suh YH.

Behav Brain Res. 2009 Jan 23;196(2):168-79. doi: 10.1016/j.bbr.2008.09.040. Epub 2008 Oct 11. Review.

PMID:
18977395
11.

Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease.

Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, Ferrante RJ, Kristal BS, Friedlander RM.

Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10483-7. Epub 2003 Aug 20.

12.

Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.

Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM.

Nat Med. 2000 Jul;6(7):797-801.

PMID:
10888929
14.

Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice.

Zhu S, Li M, Figueroa BE, Liu A, Stavrovskaya IG, Pasinelli P, Beal MF, Brown RH Jr, Kristal BS, Ferrante RJ, Friedlander RM.

J Neurosci. 2004 Jun 30;24(26):5909-12.

16.

Suppression of extracellular signal-related kinase and activation of p38 MAPK are two critical events leading to caspase-8- and mitochondria-mediated cell death in phytosphingosine-treated human cancer cells.

Park MT, Choi JA, Kim MJ, Um HD, Bae S, Kang CM, Cho CK, Kang S, Chung HY, Lee YS, Lee SJ.

J Biol Chem. 2003 Dec 12;278(50):50624-34. Epub 2003 Sep 30.

17.

Mitochondrial involvement in amyotrophic lateral sclerosis: trigger or target?

Bacman SR, Bradley WG, Moraes CT.

Mol Neurobiol. 2006 Apr;33(2):113-31. Review.

PMID:
16603792
19.

Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis.

Bordet T, Buisson B, Michaud M, Drouot C, Galéa P, Delaage P, Akentieva NP, Evers AS, Covey DF, Ostuni MA, Lacapère JJ, Massaad C, Schumacher M, Steidl EM, Maux D, Delaage M, Henderson CE, Pruss RM.

J Pharmacol Exp Ther. 2007 Aug;322(2):709-20. Epub 2007 May 11.

20.

Significant neuroprotection against ischemic brain injury by inhibition of the MEK1 protein kinase in mice: exploration of potential mechanism associated with apoptosis.

Wang X, Wang H, Xu L, Rozanski DJ, Sugawara T, Chan PH, Trzaskos JM, Feuerstein GZ.

J Pharmacol Exp Ther. 2003 Jan;304(1):172-8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk